Journal
JOURNAL OF CONTROLLED RELEASE
Volume 161, Issue 2, Pages 446-460Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2011.12.021
Keywords
Polymer therapeutics; Angiogenesis; ADME; Biodistribution; Angiogenesis-dependent diseases; Cancer
Funding
- Chief Scientist Office of the Ministry of Health, Israel [5145-300000]
- Israel Science Foundation [1309/10]
- Alon Foundation
- Israel Cancer Association
- United States-Israel Binational Science Foundation (BSF) [2007347]
- German-Israel Foundation (GIF)
- Israel Cancer Research Fund (ICRF)
- Association for International Cancer Research (AICR)
- TAU Center for Nanoscience and Nanotechnology
- Swiss Bridge
- Worldwide Cancer Research [11-0132] Funding Source: researchfish
Ask authors/readers for more resources
Polymer conjugation is an efficient approach to improve the delivery of drugs and biological agents, both by protecting the body from the drug (by improving biodistribution and reducing toxicity) and by protecting the drug from the body (by preventing degradation and enhancing cellular uptake). This review discusses the journey that polymer therapeutics make through the body, following the ADME (absorption, distribution, metabolism, excretion) concept. The biological factors and delivery system parameters that influence each stage of the process will be described, with examples illustrating the different solutions to the challenges of drug delivery systems in vivo. (c) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available